Supernus Pharmaceuticals (NASDAQ:SUPN) Director Frederick Hudson Sells 5,369 Shares of Stock

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Director Frederick Hudson sold 5,369 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $50.61, for a total transaction of $271,725.09. Following the sale, the director owned 60,413 shares of the company’s stock, valued at approximately $3,057,501.93. The trade was a 8.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Supernus Pharmaceuticals Price Performance

Shares of NASDAQ:SUPN opened at $50.21 on Tuesday. The firm has a market capitalization of $2.89 billion, a price-to-earnings ratio of -73.84, a price-to-earnings-growth ratio of 1.55 and a beta of 0.70. The business’s 50 day simple moving average is $51.23 and its 200-day simple moving average is $49.13. Supernus Pharmaceuticals, Inc. has a 12 month low of $29.16 and a 12 month high of $59.68.

Institutional Trading of Supernus Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its stake in Supernus Pharmaceuticals by 8.8% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 14,375 shares of the specialty pharmaceutical company’s stock valued at $453,000 after purchasing an additional 1,161 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH grew its holdings in shares of Supernus Pharmaceuticals by 30.4% during the second quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 85,534 shares of the specialty pharmaceutical company’s stock worth $2,696,000 after buying an additional 19,949 shares in the last quarter. Ruffer LLP acquired a new position in shares of Supernus Pharmaceuticals in the third quarter valued at approximately $2,647,000. Systematic Financial Management LP lifted its stake in shares of Supernus Pharmaceuticals by 47.5% during the second quarter. Systematic Financial Management LP now owns 245,545 shares of the specialty pharmaceutical company’s stock valued at $7,740,000 after buying an additional 79,041 shares during the period. Finally, XTX Topco Ltd purchased a new position in shares of Supernus Pharmaceuticals during the second quarter valued at approximately $1,301,000.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Craig Hallum set a $65.00 target price on Supernus Pharmaceuticals in a report on Wednesday, February 25th. Zacks Research downgraded Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Thursday, January 29th. Wall Street Zen lowered shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Sunday, March 8th. Stifel Nicolaus increased their price objective on shares of Supernus Pharmaceuticals from $50.00 to $55.00 and gave the company a “hold” rating in a research note on Friday, December 19th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Monday, December 29th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Supernus Pharmaceuticals has a consensus rating of “Hold” and an average target price of $62.17.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.